>> Ted: NEXT ON ARIZONA HORIZON, EFFORTS BY YOUNG VOTERS TO KEEP EARLY VOTING SITES ON COLLEGE CAMPUSES AND LATER IN THE HOUR, HOW THEY'RE USING VIRTUAL REALITY TO CONNECT WITH STUDENTS.

PARK GOOD EVENING AND WELCOME TO ARIZONA HORIZON.

U SUPREME COURT JUSTICE CLARENCE THOMAS KEPT LINDSEY GRAHAM TO HAVING TESTIFY IN THE INVESTIGATION OF THE 2020 HEARING.

THIS IS NOT A FORMAL RULING BUT TO CONSIDER GRAHAM'S ATTEMPTS BASED ON THE SPEECH OR DEBATE CLAUSE AND.

>>> THE DOW SUBPOENA 417 POINTS OR 1.3% AND THIS FOLLOWS LAST WEEK'S GAIN AND NASDAQ AT 5% FOR THE BIGGEST WEEKLY GAIN SINCE JUNE.

ALSO OF NOTE, TEN-YEAR AND TWO-YEAR TREASURY YIELDS WERE UP.

ROUGHLY 10% OF AMERICANS OVER 65 SUFFER FROM DEMENTIA.

FININGS ARE BASED ON RESEARCH BY THE NATIONAL INSTITUTE OF AGING AND SOCIAL SECURITY ADMINISTRATION.

THE RESULTS SHOW THAT 22% OF THOSE STUDIED HAD MILD COGNITIVE IMPAIRMENT INCLUDING FORGETTING THINGS OR APPOINTMENTS OR COMING UP WITH WORDS AND CAN ACT IMPULSIVELY AND EXERCISING CAN HELP TO KEEP THE MIND STRONG AND STAVE OFF INFLICTIONS.

ISAIAH HINZMAN HAS JOINED YOUNG VOTERS TO KEEP EARLY VOTING SITES ON COLLEGE CAMPUSES AND WE WELCOME ISAIAH HINZMAN TO ARIZONA HORIZON AND THANK YOU SO MUCH FOR JOINING US.

TALK TO US ABOUT, FIRST OF ALL, HAVE THERE BEEN VOTING SITES ON CAMPUS?

>> YES.

HERE AT THE EASTERN ARIZONA COLLEGE, THERE HAVE BEEN VOTING SITES ON CAMPUS AND IT'S USUALLY DURING VOTING DAY.

>> Ted: THERE WERE EXISTING SITES AND WHAT HAPPENED TO IT?

>> THEY STILL HAPPEN AND EASTERN ARIZONA COLLEGE, EVERY ELECTION DAY, THEY ALWAYS HAVE THIS ON HERE.

>> Ted: AND DESCRIBE THE PROCESS OF GETTING THAT VOTING SITE.

ARE YOU AWARE OF HOW LONG IT TOOK.

TALK TO US MORE ABOUT IT.

>> GETTING THIS VOTING SITE ON CAMPUS, I BELIEVE THAT THE CAMPUS ADMINISTRATORS HAD TO CONTACT OUR COUNTY, GRAND COUNTY AND THIS IS ONE OF THE SITES THAT HAVE VOTING ON CAMPUS.

>> Ted: WAS THERE ANY OPPOSITION THAT YOU WERE AWARE OF?

>> NOT TO MY KNOWLEDGE.

>> Ted: SO YOU ARE WORKING NOW TO WHAT, MAKE SURE OTHER CAMPUSES HAVE THE SAME BENEFITS YOU HAVE AT EASTERN ARIZONA COLLEGE?

>> RIGHT NOW, WE HAVE BEEN WORKING WITH MTV TO BRING EARLY VOTING ON CAMPUS.

>> Ted: EARLY VOTING, OK. AND HOW IS MTV INVOLVED IN THIS?

>> GETTING FUNDING TO HELP PUT ON EVENTS TO HELP REGISTER STUDENTS TO VOTE AND INFORM THEM ON DIFFERENT TOPICS ON WHAT THEY WOULD BE VOTING ON.

>> Ted: ON-CAMPUS SITE, I WOULD IMAGINE THEY ENCOURAGE STUDENTS TO REGISTER AND ENCOURAGE STUDENTS TO VOTE?

>> YES.

>> Ted: IS THAT WHAT YOU'RE HEARING FROM YOUR FRIENDS?

>> YES.

EVER SINCE BEFORE OCTOBER 11th OCTOBER 11th, WHEN IT WAS THE REGISTRATION IDENTITY, WE'VE BEEN HELPING STUDENTS TO GET REGISTERED TO VOTE AND INFORMING THEM WHEN TO VOTE ON EARLY VOTING DAY.

>> Ted: HOW DID YOU GET INVOLVED IN ALL OF THIS, ISAIAH?

>> OUR DEAN OF STUDENTS, HE CAME UP TO ME AND HE WAS, LIKE, WOULD YOU LIKE TO BE A PART OF THIS PROJECT TO BRING EARLY VOTING ON PROJECT?

WE HAVE PEOPLE TO DO THIS AND EXPAND EARTH EARLY VOTING, ESPECIALLY TO YOUNG VOTERS.

>> Ted: YOU HAVE AN INTEREST IN POLITICS, DON'T YOU?

>> I'VE HAD A BIG INTEREST IN U.S. HISTORY.

AS YOU CAN SEE BEHIND HERE, I HAVE POLITICAL MEMORABILIA FROM THE 1900S TO CURRENTLY.

AND I HAVE ALWAYS.

A BIG ADVOCATE FOR CIVIC ENGAGEMENT.

>> Ted: YES, INDEED.

2020, THERE WAS A RECORD TURN-OUT FOR YOUNG VOTERS AND HOW BEST DO YOU SEE TO REPEAT THAT KIND OF TURN-OUT?

>> I THINK JUST INFORMING YOUNG VOTERS ON THE IMPORTANCE OF VOTING, ESPECIALLY FOR MIDTERMS BECAUSE A LOT OF PEOPLE DON'T BELIEVE THE MIDTERMS ARE AS IMPORTANT AS GENERAL ELECTION, BUT WE'RE JUST HOPING TO SEE AN INCREASE IN YOUNG VOTER TURNOUT.

>> Ted: FOR YOU, WHAT ISSUES ARE IMPORTANT AND WHAT ABOUT YOUR FRIENDS?

>> FOR ME AND PEOPLE I TALK TO, THE KEY ISSUES ARE WHO WE'LL BE PUTTING IN THE SENATE.

RIGHT NOW, WE HAVE A SENATE SEAT IN ARIZONA UP FOR GRABS TO DETERMINE WHO HOLDS THE MAJORITY AND WE HAVE A KEY GOVERNOR RACE WHO CAN DETERMINE KEY ISSUES LIKE IMMIGRATION AND ABORTION.

>> Ted: RIGHT.

THE MTV ISSUE, AGAIN, GIVE ME A BETTER EXPLANATION OF WHAT'S GOING ON WITH IT.

MTV CAMPUS CHALLENGE AND ALL THE STUFF AND HOW THAT PLAYS INTO THIS.

>> THEIR GOAL IS TO BRING EARLY VOTING ON CAMPUS TO GIVE YOUNG VOTERS AND STUDENTS AND PEOPLE IN THE COMMUNITY A CHANCE TO HAVE A PLACE TO VOTE IN-PERSON EARLY BECAUSE THERE ARE A LOT OF PEOPLE WHO HAVE JOBS AND OTHER OUTSIDE ACTIVITIES LIKE THAT WHEN THEY'RE NOT ABLE TO GO VOTE IN-PERSON ON TUESDAY.

>> Ted: LAST QUESTION, WHAT DO YOU WANT STUDENTS TO KNOW ABOUT EARLY VOTING AND VOTING ACCESS, THE WHOLE NINE YARDS?

>> I WOULD LIKE STUDENTS TO KNOW THAT EARLY VOTING IS IMPORTANT AND VOTING IN GENERAL IS IMPORTANT IF YOU WANT TO GET YOUR VOICE OUT AND HEARD.

>> Ted: I HAVE TO ASK YOU, WHAT DO YOU PLAN ON DOING WITH YOURSELF AND WHAT ARE YOUR GOALS?

>> MY GOALS HAVE TO GO TO THE U OF A AFTER THIS AND STUDY PHARMACY.

>> Ted: STUDY PHARMACY?

>> YES.

>> Ted: THAT MAKES PERFECT SENSE.

[ Laughter ] >> ISAIAH HINZMAN, GOOD TO HAVE YOU AND BEST OF LUCK IN THIS PROJECT AND BEST OF LUCK ON YOUR FUTURE.

>> THANK YOU SO MUCH.

>> Ted: YOU BET.

UP NEXT ON ARIZONA HORIZON, THE MUHAMMAD ALI PARKINSON'S CENTER IN PHOENIX TO HELP UNDERSTAND PARKINSON'S DISEASE.

>> TONIGHT AS THE AARP SEGMENT TO OLDER ADULTS IN ARIZONA, WE LEARN ABOUT A LANDMARK STUDY THAT COULD HELP SCIENTISTS BETTER UNDERSTAND PARKINSON'S DISEASE.

IT FOCUSES ON TESTING THE ABILITY TO SMELL.

HERE IS DR. HOLLY SHILL, FROM THE MUHAMMAD ALI PARKINSON'S CENTER.

MONTREAL, JOINING US WITH THE MICHAEL J.

FOX FOUNDATION.

>> RIGHT.

>> Ted: AND IT INVOLVES, WHAT, A SMELL TEST REGARDING PARKINSONS AND THIS IS FASCINATING AND TALK TO US ABOUT THIS.

>> PEOPLE THINK ABOUT PARKINSON'S DISEASE AS TREMORS AND MOVEMENT PROBLEMS AND THAT SORT OF THING AND WHAT PEOPLE DON'T REALIZE IS THAT PARKSONS PARKINSONS START COULD BE A LOSS OF A SENSE OF SMELL.

>> Ted: THIS RESEARCH WILL LOOK INTO THIS ASPECT OF IT?

>> WE'RE TRYING TO UNDERSTAND HOW IT DEVELOPS OVER TIME AND WE KNOW A LOT ABOUT IT ONCE THE TREMORS AND MOVEMENT PROBLEMS STARTS BUT WE WANT TO TARGET PEOPLE.

IF WE'RE GETTING THERAPIES THAT SLOW PRO GUESS, WE WANT PROGRESSION, WE WANT TO LEARN ABOUT THE EARLY STAGE.

>> Ted: YOU MENTION SMELL AND THE FIRST THOUGHT IS COVID HOW PEOPLE LOST THE ABILITY TO SMELL.

>> WE HAD A MOMENT OF PANIC WHEN WE LEARNED COVID COULD CAUSE TO LEARN THE ABILITY TO SMELL AND MOST OF YOU CAN BRIEF A SIGH OF LEAF.

RELIEF.

THIS IS A TEMPORARY THING AND YOUR SENSE OF SMELL RETURNS AND PARKINSONS, IT'S DEGENERATIVE AND IT WOULD PROGRESS OVER TIME.

>> Ted: NOTHING TO LEARN FROM COVID AS FAR AS THIS IS CONCERNED?

>> WE DON'T THINK SO.

ALTHOUGH, WE'RE LOOKING AT THE AGING POPULATION AND FOLLOWING PEOPLE WHO HAVE HAD COVID AND FOLLOWING THEM OVER TIME TO SEE WHAT HAPPENS TO THEM OVER TIME.

>> Ted: YOU'RE LOOKING FOR RECRUITS?

>> THE IDEA IS THAT SOMETIMES AREN'T AWARE THEY'VE LOST THEIR SENSE OF SMELL OR LOSING THEIR SENSE OF SMELL AND NOT AWARE OF IT AND OUR BRAINS ARE GOOD AT KIND OF CONVINCING US THAT OUR SENSE OF SMELL IS GOOD.

THE WAY TO TEST IT IS TO DO AN OBOBJECTIVE TEST.

THIS IS THE UNIVERSITY OF PENNSYLVANIA SMELL IDENTIFICATION TEST AND IT'S A SCRATCH AND SNIFF OF 40 QUESTIONS TO IDENTIFY KIND OF COMMON SMELLS AND IF PEOPLE PASS, THEY'RE NORMAL AND IF NEAR ABNORMAL, THEY PARTICIPATE IN THE STUDY.

>> Ted: AS FAR AS RECRUITING, WHO ARE YOU LOOKING FOR?

>> WE'RE LOOKING FOR, FIRST OF ALL, PEOPLE THEY THEY'RE HEALTHY INDIVIDUALS OVER THE AGE OF 60 AND THOSE ARE THE PERFECT CANDIDATE.

>> Ted: NOT DIAGNOSED AND DO THEY NEED RISK FACTORS?

>> SO WE LIKE A VARIETY OF PEOPLE.

SO WE WANT PEOPLE WHO THINK THEY HAVE NO RISK FACTORS AND NOBODY IN THEIR FAMILIES WITH PARKINSONS AND NO OTHER SYMPTOMS OF TREMORS OR WHAT HAVE YOU.

WE WANT PEOPLE THAT MAY BE AT A HIGHER RISK.

MAYBE HAVE AFFECTED FAMILY MEMBER OR THEY HAVE A GENE IN THEIR FAMILY.

>> Ted: ARE THOSE THE BIGGEST RISK FACTORS, FAMILY GENES?

>> WE HAVE ANOTHER STUDY THAT'S LOOKING AT GENETICS IN PARKINSON'S DISEASE AND MAYBE IT'S 1-10 PEOPLE WITH PARKINSONS CARRY A GENE THAT.

>> Ted: IN GENERAL, HOW MUCH PROGRESS IS BEING MADE?

>> WE'RE LEARNING TREMENDOUS AMOUNTS AND I'VE BEEN DOING THIS 20 YEARS AND I FEEL LIKE WE'RE A LOT SMARTER THAN 0 20 YEARS AGO.

WE'RE MISSING THE HOLY GRAIL AND STOPS THE PROGRESSION OR REVERSES IT.

WE WOULD LIKE TO SEE THAT AND THIS STUDY WITH THE PPMI STUDY IS A STEP IN THE DIRECTION.

>> Ted: IS QUALITY OF LIFE IMPROVING?

>> WE KNOW PARKINSONS IS A DISORDER OF AGING AND AS WE GET BETTER AT JUST AGING IN GENERAL, WE ARE SEEING PATIENTS LIVE LONGER WITH PARKINSONS.

I GUESS BOTH GOOD AND BAD AND WE'RE DEALING WITH THIS SLOWLY PROGRESSIVE CONDITION THAT MAY LAST 15 OR 20 YEARS OF SOMEONE'S ADULT LIFE.

>> Ted: I THINK WE DID A SEGMENT ON THIS, THIS DEEP BRAIN STIMULATION AND IS THAT STILL A THING OR SOMETHING THAT CAN BE ENCOURAGING?

>> IT'S STILL A THING AND WE DON'T THINK OF IT AS SLOWING THE ROWTHEPROGRESSION.

IT CAN BE AN EFFECTIVE THERAPY FOR PEOPLE.

>> Ted: BRAIN HAPPENING AND STILL GOING ON?

>> YES.

RESEARCHERS THAT ARE LOOKING AT HOW YOUR BRAIN CHANGES ON NEUROIMAGING OVER TIME AND THAT'S SOMETHING WE'RE LOOKING AT IS THAT CAN PREDICT HOW YOU PROGRESS.

>> Ted: YOU WERE PREDICTING DRAMATIC CHANGES IN THE NEXT 25 YEARS.

WHY?

>> WE'RE SEEING PROMISING THINGS AND WE LEARN ABOUT THE BASIC THING AND WE SWITCH LIKE TAKING MORE VITAMINS AND GETTING WHAT'S THE BASIC BIOLOGY TO CAUSE YOU TO DEVELOP PARKINSONS AND WE'RE TARGETING PATHWAYS IN THE BRAIN WHICH WILL END UP IN PROGRESSIVE THERAPIES.

>> Ted: IN TERMS OF GROWING, PROGRESSION, THOSE OUTSIDE FACTORS, DO THEY PLAY A PART?

>> I THINK THEY DO.

WE DON'T THINK OF DIET SO MUCH.

JUST A HEART-HEALTHY DIET IS RECOMMENDING, BUT EXERCISE MAY BE KEY.

WE KNOW PEOPLE WHO CAN MAINTAIN MOBILITY CAN DO MUCH BETTER OVER THE COURSE OF THEIR ILLNESS AND WE REALLY PROMOTE THAT.

>> Ted: 25th YEAR OF THE MUHAMMAD ALI PARKINSON'S CENTER AND WE'RE STILL IN BUSINESS.

WE STARTED IN MARCH 25 YEARS AGO AND THIS IS THE 25th 25th ANNIVERSARY YEAR.

I FEEL LIKE OUR GOAL WHEN WE STARTED WHAT THEY ASKED US TO DO WAS TO TAKE CARE OF THE FAMILY.

MAKE SURE NOBODY SLIPS THROUGH THE CRACKS.

EVERYBODY GET ACCESS TO GREAT MEDICAL CARE AND GREAT SUPPORTIVE CARE AND TO LEARN ABOUT THE DISEASE AND I THINK WE'VE DONE AN AMAZING JOB OVER THE YEARS.

>> Ted: DID I SEE 50,000 PATIENTS TREATED AND COUNTING?

>> PROBABLY ABOUT RIGHT.

>> Ted: WOW!

>> WE DO 50,000 IN OUR CLINIC A YEAR.

>> Ted: LAST QUESTION, ARE YOU OPTIMISTIC?

>> AS I POINTED OUT, JUST THE TYPES OF THERAPIES THAT WE'RE SEEING TO TRY TO SLOW THE PROGRESSION OF PARKINSONS AND OUR CARE MODELS AND HOW DO WE BETTER MANAGE PARKINSONS ACROSS THE SPECTRUM AND MAKING SURE WE'RE TAKING CARE OF NOT JUST THE PATIENT AND THE CARE PARTNER, THE SPOUSE THOUGHT THE COURSE OF THE DISEASE AND IT REALLY IS THIS MULTISYSTEM EFFORT AND WE'RE GETTING THERE.

>> Ted: GREAT INFORMATION, HOLLY SHILL, THANK YOU SO MUCH.

>> YOU BET.

THANK YOU.

♪♪ >> Ted: THE IV BRAIN TUMOR CENTER AT THE BARROW NEUROLOGICAL INSTITUTE IS STREAMLINING THE APPROVAL PROCESS OF BRAIN TUMORS AND WE LEARN MORE OF OUR HEALTH PROCESS HIGHLIGHTING RESEARCH AROUND THE VALLEY AND JOINING US IS DR. NADER SANAI OF THE CENTER GOOD TO HAVE YOU.

THANK YOU SO MUCH.

GIVE ME A BETTER IDEA OF THIS IO VERY CENTER.

>> THISIVY CENTER.

>> WE'RE HERE TO FIND A CURE FOR BRAIN CANCER.

>> Ted: THIS IS IN THE COUNTRY OR WORLD?

>> THERE ARE MORE BRAIN TUMOR PATIENTS THAN ANY OTHER STATE IN THE UNITED STATES AND BECAUSE OF THE BARROW THAN ANY OTHER CENTER IN THE UNITED STATES.

SO FOR THE IVY CENTER, THESE ARE THE PATIENTS WE'RE SERVING AND HERE TO PROVIDE THEM WITH CLINICAL CARE AND FIND CLINICAL TREATMENTS AND THERAPIES.

>> Ted: THIS INCLUDES PHASE 0 CLINICAL TRIALS AND WHAT ARE THOSE?

>> SO CONVENTIONAL CLINICAL TRIALS AND WE'RE FAMILIAR WITH OPTIONS FOR PATIENTS THAT DON'T HAVE STANDARD OPTIONS AND THEY TYPICALLY INVOLVE A NEW DRUG THAT IS GIVEN TO THE PATIENT ON FAITH WITH AN ESTIMATED GUESS THAT IT WILL HELP.

PHASE 0 TRIALS KIND OF TAKES IT ONE STEP FURTHER AND WHAT WE DO IS WE GIVE THE PATIENTS A SMALL EXPOSURE OF AN EXPERIMENTAL DRUG BEFORE SURGERY SO THAT WHEN A SOUTHERN LIKE MYSELF THAT TAKES A BRAIN TUMOR OUT, WE CAN TEST IT AND SAY IS THIS WORKING IN THIS INDIVIDUAL PATIENT AND GETTING THERE AND HITTING THE TARGET AND WITHIN A WEEK OF SURGERY, WE GIVE THEM THAT ANSWER SO THAT WE KNOW WHETHER IT MAKES SENSE TO PUT THIS INDIVIDUAL PATIENT ON THIS INDIVIDUAL EXPERIMENTAL DRUG.

>> Ted: THAT MAKES PERFECT SENSE.

YOU EXPOSE, REMOVE AND LOOK AT WHAT YOU'VE REMOVED AND IF EXPOSURE IS WORKING AND HOW DO YOU KNOW IT'S WORKING?

>> SO FOR ALL THESE DRUG, WE HAVE ELABORATE TESTS IN ADVANCE.

THIS IS OUR BREAD AND BUTTER AND WHY WE CAN TO THESE TYPES OF THINGS AT OUR CENTER.

WE GET THAT TISSUE, WE ASK THE TWO MOST IMPORTANT QUESTIONS FOR ANY NEW DRUG, IS IT GETTING TO THAT TUMOR?

BECAUSE TUMORS ARE IN THE BRAIN AND IT MEANS MANY DRUGS GET IN AND HITTING THE RIGHT TARGETS IN THAT TUMOR.

>> Ted: TALK MORE ABOUT THE BLOOD-BRAIN BEAR REMEMBER BARRIER AND WE NEVER THINK ABOUT IT AND THAT IS A THING, ISN'T IT?

>> THE NUMBER ONE OBSTACLE FOR DRAWING DEVELOPMENT FOR ANYTHING IN THE BRAIN.

THE BLOOD-BRAIN BARRIER IS DESIGNED TO PROTECT OUR BRAIN FROM THINGS WE CONSUME SO OTHER THINGS WE TAKE DON'T GET THAT UNNECESSARILY.

>> Ted: YOU FIND OUT RELATIVELY QUICKLY WHETHER OR NOT THIS IMPACTS THE TUMOR.

LET'S SAY IT DOES.

THEN WHAT HAPPENS?

>> WELL, THEN THAT PATIENT HAS SOME CONFIDENCE THAT THIS EXPERIMENTAL THERAPY IS WORTH GOING ON.

ALL OF THESE THERAPIES HAVE SIDE EFFECTS.

THERE ARE RISKS TO THEM AND, OBVIOUSLY, THIS IS A DANGEROUS DISEASE FOR THESE PATIENTS.

BUT THEY CAN GO FORWARD WITH CONFIDENCE KNOWING, OK, I'M NOT WASTING MY TIME ON THIS AND TIME IS THE MOST IMPORTANT COMMODITY AND WE WANT THEM TO BE ON SOMETHING THAT WORKS.

>> Ted: IF IT PROVES IT'S NOT WORKING OR MAKING ADIFFERENCE, THE WEIGHT WOULD GET ON A DIFFERENT CLINICAL TRIAL.

>> WE GO FROM THE RECOVERY PHASE TO GETTING THEM ON ANOTHER EXPERIMENTAL THERAPY.

>> Ted: LAB ANIMALS, HOW DOES THAT PLAY INTO ALL OF THIS?

>> DRUG DEVELOPMENT THIS GENERAL IS SOMETHING THAT BEGINS IN THE ANIMAL PHASE OF TESTING.

THE CHALLENGE FOR BRAIN CANCER PATIENTS, UNLIKE OTHER CANCERS, THERE ARE NOT GOOD ANIMAL MODELS FOR BRAIN CANCER AND WE HAVE MANY EXAMPLES THAT SEEM TO WORK IN THE LABORATORY AND DON'T WORK IN PATIENTS AND THIS IS WHY WE EMPHASIZE THIS PHASE OF TRIALING.

>> Ted: TO WE KNOW WHY THAT IS?

>> WE THINK BECAUSE THE HUMAN BRAIN IS UNLIKE ANYTHING ELSE IN ANY OTHER ANIMAL.

WHEN A HUMAN HAS SKIN CANCER OR BREAST CANCER, THE EQUIVALENT IN ANIMALS IS ALMOST IDENTICAL.

IT'S DIFFERENT FROM PATIENT TO PATIENT THAT IT CAN'T BE RECAPITULATED IN ANIMALS.

>> Ted: THIS IS LIKE A MOVING GOAL POST FOR SOME, IS IT NOT?

>> THE MOST COMMON TYPE WE'RE FAMILIAR WITH IS LIKE GLEE YO BLASTOMA.

IT IS A MOVING TARGET BECAUSE IT'S INDIVIDUALIZED FROM PATIENT TO PATIENT.

>> Ted: HOW MUCH DO WE KNOW ABOUT BRAIN CANCER, PREVENTION, DIET AND IS IT GENETICS?

>> PREVENTING THOSE IS PREVENTING THE PRIMARY CANCERS BUT THE ONES THAT ARE IN THE BRAIN ITSELF, THEY HAPPEN SPONTANEOUSLY.

RANDOM MUTATIONS AND 99% OF THE TIME, THERE'S TO PREDISPOSING FACTORS.

>> Ted: NEW HEADQUARTERS OPENING UP.

>> THE IVY BRAIN TUMOR CENTER IS A SURGING EFFORT AND OVER 60 FULL-TIME EMPLOYEES, $150 MILLION OF COMMITTED FUNDS COMMITTING A GLOBAL HEADQUARTERS DOWNTOWN, AT THE BARRON INSTITUTE AND THIS IS A HOME FOR PATIENTS AND INVESTIGATORS ALIKE AND PATIENTS WILL BE TREATED IN THE SAME BUILDING THAT INVESTIGATORS LIKE MYSELF ARE WORKING ON THEIR PROBLEM.

>> Ted: THAT SOUNDS ENCOURAGING AND WORLD'S LARGEST TRANSLATIONAL RESEARCH CENTER.

WHAT DOES TRANSLATIONAL MEAN?

>> THE APPLICATION OF SCIENCE TO A HUMAN.

SO WE HAVE MANY IMPORTANT DISCOVERIES IN SCIENCE, BUT OUR EFFORT IS REALLY FOCUSED ON GETTING THOSE DISCOVERIES INTO PATIENTS.

>> Ted: GET THEM INTO PATIENTS AS QUICKLY AND EFFECTIVELY AS POSSIBLE.

>> THAT'S RIGHT.

THE PATIENTS THAT HAVE THIS DISEASE TODAY, NOT THE ONES NEXT YEAR, NEXT DECADE AND FOCUSED ON NOW AND FOR OUR PATIENTS, OUR FOCUS IS GET THEM SOMETHING NEW THAT WILL WORK.

>> Ted: LAST QUESTION, ARE YOU WORKING IN CONJUNCTION WITH ANY OTHER PROGRAMS, ANY OTHER HOSPITALS INSTITUTES AROUND THE COUNTRY?

>> THE IVY CENTER ITSELF IS ACTUALLY PARTNERED WITH MULTIPLE HOSPITAL CENTERS IN THE VALLEY ON HEALTH AS WELL AS COMMON SPIRIT.

BUT WE HAVE AFFILIATIONS WITH COMMUNITIES FAR AND WIDE FROM NEWHAVEN, CONNECTICUT, YALE TO UCSF.

>> Ted: DR. NADER SANAI, GOOD TO HAVE YOU AND THANK YOU FOR JOINING US.

>> THANK YOU FOR HAVING ME.

>> Ted: THAT'S IT FOR NOW AND THANK YOU SO MUCH FOR JOINING US AND YOU HAVE A GREAT EVENING!